News
3d
Zacks.com on MSNAstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 ...
Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a ...
AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate (ADC) Datroway has been granted accelerated approval from the FDA for a lung cancer indication, seven months after ...
TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...
AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate for breast cancer, TROP2-directed Datroway.
Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...
The FDA has granted accelerated approval to Datroway for adults with previously-treated, locally advanced or metastatic EGFR-mutated NSCLC.
Read about AstraZeneca PLC ADR (AZN:XNAS) stock and today's latest news and financial updates.
Review the current AstraZeneca PLC ADR (AZN:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if AZN is the best investment for you.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results